Global Biogeneric Drugs Market Size By Type (Insulins, Growth Hormones), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Biogeneric Drugs Market was valued at USD 16.2 billion in 2023 and is projected to surpass USD 34.7 billion by 2031, growing at a CAGR of 9.8% during the forecast period from 2023 to 2031. Biogeneric drugs—also known as biosimilars—are cost-effective alternatives to original biologic drugs and play a pivotal role in expanding access to advanced therapies. The market is experiencing robust growth driven by increasing patent expirations of biologic drugs, the rising burden of chronic diseases, and escalating healthcare costs globally. Biogenerics are gaining widespread acceptance across therapeutic areas such as oncology, autoimmune disorders, and diabetes, thereby boosting market momentum.

Drivers

1. Rising Prevalence of Chronic Diseases

The increasing global incidence of chronic conditions like cancer, rheumatoid arthritis, and diabetes is significantly driving demand for biogeneric drugs, which offer comparable efficacy at lower costs than branded biologics.

2. Expiring Patents of Major Biologics

As patents for blockbuster biologic drugs expire, biosimilar manufacturers are entering the market, offering similar therapeutic benefits and creating intense competition, which enhances market accessibility and affordability.

3. Government Incentives and Policy Support

Regulatory bodies such as the FDA and EMA are streamlining approval pathways for biosimilars. Favorable healthcare policies and public reimbursement schemes are accelerating market adoption, especially in developed countries.

Restraints

1. Complex Manufacturing Processes

Biogeneric drugs require sophisticated manufacturing capabilities and stringent regulatory compliance, resulting in high development costs and extended approval timelines, which can limit entry for smaller firms.

2. Physician and Patient Reluctance

Despite clinical equivalence, there remains skepticism among some physicians and patients regarding the efficacy and safety of biosimilars compared to original biologics, which can hamper market penetration.

Opportunity

1. Expanding Access in Emerging Markets

Rapid healthcare infrastructure development in Asia-Pacific, Latin America, and parts of Africa is creating new opportunities for biogeneric drug manufacturers. Government efforts to curb healthcare expenses are further encouraging biosimilar uptake.

2. Rising R&D Collaborations and Licensing Agreements

Pharmaceutical companies are increasingly engaging in strategic partnerships and licensing deals to co-develop and commercialize biosimilars, thereby accelerating innovation and expanding product pipelines.

Market by System Type Insights

Based on system type, Monoclonal Antibodies (mAbs) emerged as the largest segment in 2023. mAbs are widely used in the treatment of cancer, autoimmune diseases, and infectious conditions, and the availability of biosimilar versions has significantly broadened patient access. This segment is expected to retain dominance due to ongoing innovations and high treatment costs associated with original biologics.

Market by End-use Insights

In 2023, Hospitals and Specialty Clinics held the largest market share among end-users. These facilities represent the frontline for treating complex and chronic conditions that often require biologic therapy. Institutional procurement of cost-effective biogenerics ensures optimized resource allocation, especially in large patient care centers.

Market by Regional Insights

North America dominated the global biogeneric drugs market in 2023, driven by robust healthcare infrastructure, early adoption of biosimilars, and clear regulatory frameworks. However, Asia-Pacific is poised to witness the fastest growth during the forecast period due to increasing healthcare access, favorable government policies, and rising chronic disease prevalence.

Competitive Scenario

Key players in the global biogeneric drugs market include:

Amgen Inc.

Pfizer Inc.

Sandoz (a Novartis division)

Biocon Biologics Ltd.

Samsung Bioepis

Celltrion Inc.

Mylan N.V. (part of Viatris)

Teva Pharmaceutical Industries Ltd.

These companies are actively investing in biosimilar development, manufacturing capacity expansion, and global market penetration through partnerships, regulatory approvals, and product launches.

Scope of Work – Global Biogeneric Drugs Market

Key Market Developments

March 2023: Biocon Biologics acquired the biosimilars business of Viatris, strengthening its product portfolio and global footprint.

July 2023: Pfizer launched a biosimilar version of adalimumab in the U.S. to compete with Humira.

November 2024: Celltrion received EMA approval for its biosimilar infliximab, expanding its European presence.

FAQs

1) What is the current market size of the Global Biogeneric Drugs Market?

The Global Biogeneric Drugs Market was valued at USD 16.2 billion in 2023.

2) What is the major growth driver of the Global Biogeneric Drugs Market?

The primary growth driver is the increasing prevalence of chronic diseases and the expiration of patents on major biologics.

3) Which is the largest region during the forecast period in the Global Biogeneric Drugs Market?

North America is the largest market, while Asia-Pacific is projected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Biogeneric Drugs Market?

The Monoclonal Antibodies (mAbs) segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Biogeneric Drugs Market?

Major players include Amgen, Pfizer, Sandoz, Biocon, Samsung Bioepis, Celltrion, and Viatris.